The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials

The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials Silvana Martino, Joseph Costantino, Michelle McNabb, John Mershon, Katherine Bryant, Trevor Powles, Roberta J. Secrest Oncologist 2004; 9: 116-125 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the tamoxifen breast cancer prevention trials and the general risk-benefit profile of tamoxifen for breast cancer prevention. Compare and contrast the tamoxifen breast cancer chemoprevention trials with the ongoing raloxifene chemoprevention trials in terms of study design and baseline patient characteristics. Describe the limitations of the completed and ongoing tamoxifen and raloxifene breast cancer chemoprevention trials and the areas for future breast cancer chemoprevention research. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 26, 2004 Most Recent Review: Mar. 26, 2004* Most Recent Update: Mar. 26, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.